Recombinant Horse T-cell surface antigen CD2 (CD2)

What is the molecular structure of equine CD2 and how does it compare to other species?

Equine CD2 is a T-lymphocyte glycoprotein with a cDNA containing an open reading frame of 1041 bp, encoding a translated product of 347 amino acids. The protein shares 50-65% sequence identity with human, rat, and mouse CD2 homologues, with the greatest similarity to human CD2 . The full-length mature equine CD2 protein spans amino acids 25-347 .

Evolutionarily conserved structural features include:

• Core residues that preserve the structural integrity of the molecule

• A critical linker region that maintains the unique domain organization

• An array of highly charged residues in the putative ligand-binding face

• Specific glycosylation-signal distributions that render the ligand-binding GFCC'C" face of domain 1 relatively unhindered by glycosylation

How can recombinant horse CD2 be produced for research purposes?

Recombinant full-length horse T-cell surface antigen CD2 can be produced using the following methodology:

• Expression System: The protein (amino acids 25-347) can be expressed in E. coli with an N-terminal His tag .

• Purification: The expressed protein can be purified to >90% purity as determined by SDS-PAGE .

• Storage Considerations:

  • Store at -20°C/-80°C upon receipt

  • Aliquoting is necessary for multiple use

  • Avoid repeated freeze-thaw cycles

  • Working aliquots can be stored at 4°C for up to one week

• Reconstitution Protocol:

  • Centrifuge vial briefly before opening

  • Reconstitute in deionized sterile water to 0.1-1.0 mg/mL

  • Add 5-50% glycerol (final concentration) for long-term storage at -20°C/-80°C

How can recombinant horse CD2 be used to study T cell activation in equine immunology?

Recombinant horse CD2 can be applied in multiple experimental approaches to investigate T cell activation:

• IL-2Rα (CD25) Expression Analysis: Equine leukocytes can be stimulated with phorbol 12-myristate 13-acetate (PMA) for 72 hours, followed by staining for IL-2Rα expression on CD4+ or CD8+ T lymphocytes using biotinylated recombinant human IL-2 and specific monoclonal antibodies .

• T Cell Polarization Studies: CD2 can be used to investigate T cell polarization dynamics during antigen recognition, particularly focusing on the redistribution of CD2 molecules to the uropod during T cell scanning of antigen-presenting cells .

• Functional Assays:

  • Recombinant CD2 can be incorporated into assays measuring T cell proliferation, cytokine production, and activation marker expression

  • The effects of CD2 on T cell responses can be assessed through comparison of CD2-sufficient and CD2-deficient systems

What methodological approaches can be used to study CD2's role in T cell scanning?

To investigate CD2's role in T cell scanning of antigen-presenting cells (APCs), researchers can employ these methodological approaches:

• Time-lapse Differential Interference Contrast and Immunofluorescence Microscopy:

  • Use digitized time-lapse DIC and immunofluorescence microscopy on living cells to monitor CD2 redistribution during T cell-APC interactions

  • This technique revealed that CD2 molecules rapidly redistribute on interaction with cellular substrata, resulting in a 100-fold greater CD2 density in the uropod versus the leading edge

• CD2-Ligand Blocking Experiments:

  • Preincubate APC monolayers with anti-CD58 mAb before plating T cells

  • Measure the percentage of scanning T cells bound to monolayers with and without blocking antibodies

  • Use CD58 mutants (e.g., K34A and K87A) with reduced CD2 binding activity as alternative approaches

• Molecular Distribution Analysis:

  • Track distribution of surface molecules (CD2, CD3, lipid rafts, CD45, CD11a/CD18) on T cells during scanning

  • Monitor formation of "presynapse" structures and molecular compartmentalization within the uropod

How can researchers investigate the quantitative effect of CD2 on T cell antigen recognition threshold?

To study CD2's role in modulating T cell recognition thresholds, implement these methodological approaches:

• TCR Transgenic Models:

  • Cross CD2-deficient mice with TCR-transgenic mice specific for defined antigens (e.g., viral peptides)

  • Compare responses of CD2-sufficient and CD2-deficient T cells to varying concentrations of cognate peptide

  • Current research shows CD2-deficient T cells require 3-10 fold more peptide to produce equivalent responses

• Altered Peptide Ligand Experiments:

  • Use altered peptide ligands with different affinities for the TCR

  • The effect of CD2 is more pronounced when using lower affinity peptides, suggesting CD2 may reduce the minimum affinity threshold for T cell activation

• In Vivo Transfer Models:

  • Transfer equal numbers of CD2-deficient and CD2-sufficient TCR-transgenic T cells into recipient mice

  • Challenge with antigens at different concentrations (e.g., replication-competent virus versus inactivated virus)

  • Monitor differential expansion of the two T cell populations

• TCR Downmodulation Analysis:

  • Measure TCR downmodulation as a proxy for TCR/peptide-MHC engagement

  • Compare the extent of downmodulation between CD2-sufficient and CD2-deficient T cells

What experimental designs can be used to study the cis interactions between CD2 and its ligands on T cells?

Recent research has revealed unexpected cis interactions between CD2 and its ligands on the same T cell. To investigate this phenomenon:

• Genetic Knockout Approaches:

  • Generate and characterize T cells with either CD2 or CD48 (in mice) or CD58 (in humans) knocked out

  • Compare activation defects in single knockouts versus double knockouts

  • Test if ligand expression on the same T cell is sufficient for CD2 activation

• Functional Assays for Cis Activation:

  • Design experiments where T cells expressing only CD2 or only its ligand are co-cultured

  • Compare to T cells expressing both molecules to distinguish cis from trans interactions

  • Measure various T cell activation parameters (proliferation, cytokine production, signaling)

• Imaging Techniques:

  • Use high-resolution imaging methods (super-resolution microscopy, FRET) to visualize cis interactions

  • Track the spatial organization of CD2 and its ligands on the T cell surface during activation

How can equine CD2 research inform potential immunotherapeutic approaches?

Studies on equine CD2 can contribute to immunotherapeutic research through:

• Comparative Immunology Approaches:

  • Compare CD2 function across species (equine, human, mouse, rat) to identify conserved therapeutic targets

  • Study species-specific differences in CD2-ligand interactions to predict therapeutic efficacy across species

• Anti-CD2 Antibody Development:

  • Design and test monoclonal antibodies against equine CD2

  • Evaluate antibody effects on T cell function in vitro and in vivo

  • Compare to known therapeutic anti-CD2 antibodies like BTI-322

• Mixed Lymphocyte Reaction (MLR) Models:

  • Use experimental systems similar to those studying BTI-322 effects on xenogeneic MLR

  • Measure [³H]-TdR incorporation to assess T cell proliferation in the presence of anti-CD2 antibodies

  • Evaluate primary and secondary responses to determine long-term immunomodulatory effects

How can researchers investigate the role of CD2 in overcoming T cell exhaustion and resistance to cancer immunotherapies?

Recent findings suggest CD2-CD58 interactions may help overcome resistance to cancer immunotherapies. To investigate this:

• Correlation Studies in Clinical Samples:

  • Analyze CD2 expression levels and correlate with survival rates in cancer patients

  • Current research shows increased CD2 expression correlates with improved survival in melanoma, breast cancer, AML, and DLBCL

• Resistance Mechanism Investigation:

  • Examine CD58 downregulation in tumors resistant to immune checkpoint inhibitors (ICIs), CAR T-cell, or R-CHOP therapies

  • Compare CD58 expression between responders and non-responders to immunotherapies

• Single-cell RNA Sequencing Approaches:

  • Use scRNA-seq to examine CD2 expression in tumor-infiltrating lymphocytes based on:

    • Differentiation status (CD8+TCF7+ or CD8+Tox+)

    • Clinical response to ICI treatment

  • Compare CD2 expression levels in CAR T-cell infusion products from patients with complete remission versus progressive disease

What methods can be used to analyze the structural features of recombinant horse CD2 and compare them across species?

To analyze structural features of equine CD2 and perform cross-species comparisons:

• Structure-Based Sequence Analysis:

  • Compare sequences of equine, human, mouse, and rat CD2 homologues in the context of the crystal structure (e.g., rat soluble CD2)

  • Identify conserved residues in the core, linker region, and ligand-binding face

• Glycosylation Pattern Analysis:

  • Map glycosylation-signal distributions in the equine CD2 sequence

  • Compare to glycosylation patterns in other species

  • Determine how glycosylation affects the putative ligand-binding face

• Expression Analysis:

  • Use Northern blotting to analyze mRNA expression in different tissues (spleen, thymus, activated peripheral lymphocytes)

  • Compare expression patterns across species

How can researchers investigate the molecular mechanisms by which CD2 enhances T cell antigen recognition?

To elucidate the mechanisms underlying CD2's enhancement of T cell antigen recognition:

• Membrane Distance Measurement:

  • Investigate how CD2-ligand interactions position the membranes of T cells and APCs at separation distances optimal for TCR engagement of peptide-MHC (approximately 14 nm)

  • Compare effects of wild-type versus engineered CD2-ligand complexes of different dimensions

• Modified CD2-Ligand Interaction Studies:

  • Create elongated CD2-ligand interactions (>21 nm) to test the hypothesis that proper membrane spacing is critical

  • Current research shows that while wild-type CD2-ligand interactions enhance T cell antigen recognition, elongated interactions are strongly inhibitory

• Close Contact Zone Analysis:

  • Investigate formation of "close contact zones" where CD2-ligand interactions optimize membrane separation for TCR engagement

  • Study how these zones affect the spatial distribution of TCRs and their access to peptide-MHC complexes

How should researchers interpret contradictory findings between mouse and human CD2 studies?

When analyzing contradictory findings between mouse and human CD2 studies, researchers should consider:

• Affinity Differences:

  • Human CD2 binds its major ligand (CD58) with 5-10 fold greater solution affinity than mouse CD2 binds CD48

  • The difference in physiologically relevant "two-dimensional" affinity is even greater (40-50 fold)

• Expression Pattern Variations:

  • CD58 (human CD2 ligand) is widely expressed in both hematopoietic and nonhematopoietic cells

  • CD48 (mouse CD2 ligand) expression is largely confined to hematopoietic cells and endothelium

  • These differences may account for the more subtle phenotypes observed in CD2-deficient mice

• Relative Dependency Differences:

  • Mouse T cells appear less dependent than human T cells on CD2-ligand interactions

  • Consider species-specific differences when extrapolating findings across species

• Experimental System Variations:

  • In vitro blocking antibody studies versus genetic knockout approaches may yield different results

  • The background of TCR transgenic models can influence the observed phenotype

How can researchers reconcile the finding that CD2 plays both positive and negative roles in T cell development versus peripheral T cell activation?

To address the apparent contradiction between CD2's roles in development versus peripheral activation:

• Stage-Specific Analysis:

  • Design experiments to analyze CD2 function at discrete stages of T cell development

  • Compare CD2 effects on pre-TCR signaling in DN thymocytes versus TCR signaling in DP and SP thymocytes

• TCR Affinity Considerations:

  • Investigate how CD2 affects selection of T cells bearing TCRs with different affinities for self-peptide-MHC

  • Current research suggests CD2 may allow immature thymocytes with relatively high TCR affinities to escape negative selection

• Signaling Pathway Comparison:

  • Compare CD2-mediated signaling pathways in thymocytes versus peripheral T cells

  • Investigate potential differences in CD2 cross-talk with the TCR complex between developing and mature T cells

• Cytoplasmic Domain Function Analysis:

  • Human CD2 transgenic mouse experiments suggest the cytoplasmic tail plays a key role in thymocyte maturation

  • Investigate signaling pathways activated by the CD2 cytoplasmic domain in developing versus mature T cells